Fertilizers & Agrochemicals
Shivalik Rasayan Limited produces and sells chemicals for the protection of plants in India. The company offers Dimethoate technical, which is used in the preparation of formulations for use in the control of various insects and mites; and Malathion technical, an organophosphorus based contact insecticide used in the agricultural production of various food/feed crops. It also manufactures organophosphorus-based insecticides and chemicals. In addition, it develops and manufactures active pharmaceutical ingredients in oncology, ARVs, cardiovascular, metabolic disorders, and immunology; and manufactures oncology and non-oncology products. Further, the company offers custom manufacturing of chemicals. Shivalik Rasayan Limited was incorporated in 1979 and is based in New Delhi, India. ]
Analysis of Shivalik Rasayan's financial performance, highlighting revenue trends, growth patterns, and key metrics through quarterly analysis.
Last Updated: Dec 31, 2024
Description | Share | Value |
---|---|---|
Pharma Formulation | 52.9% | 45.1 Cr |
Agrochemicals | 44.4% | 37.9 Cr |
Active Pharma Ingredients (API) | 2.7% | 2.3 Cr |
Total | 85.3 Cr |
Balance Sheet: Strong Balance Sheet.
Smart Money: Smart money has been increasing their position in the stock.
Growth: Good revenue growth. With 49.6% growth over past three years, the company is going strong.
Momentum: Stock is suffering a negative price momentum. Stock is down -7.9% in last 30 days.
Size: It is a small market cap company and can be volatile.
Technicals: SharesGuru indicator is Bearish.
Comprehensive comparison against sector averages
SHIVALIK metrics compared to Fertilizers
Category | SHIVALIK | Fertilizers |
---|---|---|
PE | 46.61 | 54.03 |
PS | 2.87 | 2.35 |
Growth | 18.5 % | 4.4 % |
SHIVALIK vs Fertilizers (2022 - 2025)
Understand Shivalik Rasayan ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
Shareholder Name | Holding % |
---|---|
Growel Remedies Limited | 47.37% |
Ginnerup Capital ApS | 3.22% |
India Emerging Giants Fund Limited | 2.48% |
Eric Aarestrup Sorensen | 2.13% |
Sanjay Bansal | 1.9% |
FL Dadabhoy | 1.04% |
Ritesh Kantilal Oswal | 1.02% |
Distribution across major stakeholders
Distribution across major institutional holders
Investor Care | |
---|---|
Dividend Yield | 0.16% |
Dividend/Share (TTM) | 1 |
Shares Dilution (1Y) | 0.00% |
Diluted EPS (TTM) | 10.41 |
Financial Health | |
---|---|
Current Ratio | 1.68 |
Debt/Equity | 0.19 |
Debt/Cashflow | -0.08 |
Valuation | |
---|---|
Market Cap | 910.36 Cr |
Price/Earnings (Trailing) | 46.61 |
Price/Sales (Trailing) | 2.87 |
EV/EBITDA | 19.04 |
Price/Free Cashflow | -9.18 |
MarketCap/EBT | 40.48 |
Fundamentals | |
---|---|
Revenue (TTM) | 317.7 Cr |
Rev. Growth (Yr) | 21.15% |
Rev. Growth (Qtr) | 4.97% |
Earnings (TTM) | 19.53 Cr |
Earnings Growth (Yr) | 52.81% |
Earnings Growth (Qtr) | 49.93% |
Profitability | |
---|---|
Operating Margin | 7.08% |
EBT Margin | 7.08% |
Return on Equity | 3.85% |
Return on Assets | 2.73% |
Free Cashflow Yield | -10.9% |